286 related articles for article (PubMed ID: 31483883)
1. Impact of ultrasonographic features, cytomorphology and mutational testing on malignant and indeterminate thyroid nodules on diagnostic accuracy of fine needle cytology samples: A prospective analysis of 141 patients.
Fulciniti F; Cipolletta Campanile A; Malzone MG; Chiofalo MG; Capiluongo A; Monaco M; Di Maio N; Sandomenico F; Botti G; Chiappetta G; Vuttariello E; Pezzullo L
Clin Endocrinol (Oxf); 2019 Dec; 91(6):851-859. PubMed ID: 31483883
[TBL] [Abstract][Full Text] [Related]
2. PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.
Halászlaki C; Tóbiás B; Balla B; Kósa JP; Horányi J; Bölöny E; Nagy Z; Speer G; Járay B; Székely E; Istók R; Székely T; Putz Z; Dank M; Lakatos P; Takács I
Endocr Pract; 2016 Sep; 22(9):1081-7. PubMed ID: 27214302
[TBL] [Abstract][Full Text] [Related]
3. Value of
Chen X; Zhou Q; Wang F; Zhang F; Du H; Zhang Q; Wu W; Gong X
AJNR Am J Neuroradiol; 2018 Dec; 39(12):2360-2365. PubMed ID: 30498021
[TBL] [Abstract][Full Text] [Related]
4. Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China.
Guo HQ; Zhao H; Zhang ZH; Zhu YL; Xiao T; Pan QJ
Dis Markers; 2014; 2014():912182. PubMed ID: 24591770
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Limitation of Fine-Needle Aspiration (FNA) on Indeterminate Thyroid Nodules Can Be Partially Overcome by Preoperative Molecular Analysis: Assessment of RET/PTC1 Rearrangement in BRAF and RAS Wild-Type Routine Air-Dried FNA Specimens.
Ko YS; Hwang TS; Kim JY; Choi YL; Lee SE; Han HS; Kim WS; Kim SK; Park KS
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417935
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany.
Eszlinger M; Böhme K; Ullmann M; Görke F; Siebolts U; Neumann A; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Ruschenburg I; Paschke R
Thyroid; 2017 Mar; 27(3):402-411. PubMed ID: 28071986
[TBL] [Abstract][Full Text] [Related]
7. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
8. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study.
Bardet S; Goardon N; Lequesne J; Vaur D; Ciappuccini R; Leconte A; Monpeyssen H; Saguet-Rysanek V; Clarisse B; Lasne-Cardon A; Ménégaux F; Leenhardt L; Buffet C
Endocrine; 2021 Feb; 71(2):407-417. PubMed ID: 32638211
[TBL] [Abstract][Full Text] [Related]
10. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.
Rossi M; Buratto M; Tagliati F; Rossi R; Lupo S; Trasforini G; Lanza G; Franceschetti P; Bruni S; Degli Uberti E; Zatelli MC
Thyroid; 2015 Feb; 25(2):221-8. PubMed ID: 25333496
[TBL] [Abstract][Full Text] [Related]
11. Multiplex PCR approach to simultaneously identify several mutations in fine needle cytology thyroid samples.
Vuttariello E; Borra M; Mauriello E; Calise C; D'Andrea B; Capiluongo A; Fulciniti F; Cipolletta A; Monaco M; Pezzullo L; Chiappetta G
Oncotarget; 2017 Jul; 8(30):49351-49358. PubMed ID: 28537891
[TBL] [Abstract][Full Text] [Related]
12. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
13. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
[TBL] [Abstract][Full Text] [Related]
14. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
15. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.
Nikiforov YE; Ohori NP; Hodak SP; Carty SE; LeBeau SO; Ferris RL; Yip L; Seethala RR; Tublin ME; Stang MT; Coyne C; Johnson JT; Stewart AF; Nikiforova MN
J Clin Endocrinol Metab; 2011 Nov; 96(11):3390-7. PubMed ID: 21880806
[TBL] [Abstract][Full Text] [Related]
16. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis.
Marchetti I; Iervasi G; Mazzanti CM; Lessi F; Tomei S; Naccarato AG; Aretini P; Alberti B; Di Coscio G; Bevilacqua G
Thyroid; 2012 Mar; 22(3):292-8. PubMed ID: 22181337
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application.
Guerra A; Sapio MR; Marotta V; Campanile E; Moretti MI; Deandrea M; Motta M; Limone PP; Fenzi G; Rossi G; Vitale M
Endocr J; 2011; 58(1):31-8. PubMed ID: 21173509
[TBL] [Abstract][Full Text] [Related]
18. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
19. Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study.
Marina M; Zatelli MC; Goldoni M; Del Rio P; Corcione L; Martorana D; Percesepe A; Bonatti F; Mozzoni P; Crociara A; Ceresini G
J Endocrinol Invest; 2021 Dec; 44(12):2635-2643. PubMed ID: 33860907
[TBL] [Abstract][Full Text] [Related]
20. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]